Table 1.
Univariate and multivariate analysis for event-free survival
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| n | 5y EFS (95% CI) | P value | Hazard ratio (95% CI) | P value | ||
| Age at HSCT, years old | 0–4 | 144 | 73.3 (65.1–79.9) | 0.918 | ref | |
| 5–9 | 78 | 68.2 (55.9–77.7) | 0.83 (0.44–1.57) | 0.575 | ||
| 10–15 | 77 | 68.2 (56.0–77.6) | 0.77 (0.38–1.55) | 0.466 | ||
| TNC* | < median | 147 | 69.8 (61.4–76.8) | 0.772 | ||
| ≥ median | 147 | 71.2 (62.9–78.1) | ||||
| CD34 + cells* | < median | 143 | 65.1 (56.3–72.6) | 0.093 | ||
| ≥ median | 143 | 76.3 (68.1–82.7) | ||||
| KIR-L | match | 238 | 69.8 (63.2–75.4) | 0.490 | ||
| mismatch | 61 | 74.0 (60.4–83.5) | ||||
| KIR-L and CD34 | KIR-L match-CD34 low | 112 | 67.0 (57.1–75.2) | 0.096 | ref | |
| KIR-L mismatch-CD34 low | 31 | 58.0 (37.9–73.7) | 1.22 (0.59–2.50) | 0.590 | ||
| KIR-L match-CD34 high | 115 | 73.4 (63.9–80.7) | 0.77 (0.44–1.35) | 0.355 | ||
| KIR-L mismatch-CD34 high | 28 | 89.1 (70.0–96.4) | 0.19 (0.04–0.85) | 0.029 | ||
| CR status at HSCT | CR1 | 212 | 73.4 (66.6–79.0) | 0.255 | ref | |
| CR2 | 87 | 63.9 (52.5–73.3) | 1.35 (0.81–2.23) | 0.249 | ||
| HSCT Year | 2000–2009 | 97 | 66.6 (56.2–75.1) | 0.393 | ref | |
| 2010–2021 | 202 | 72.4 (65.2–78.3) | 1.48 (0.86–2.56) | 0.158 | ||
| HCT-CI | 0 | 219 | 72.9 (66.2–78.5) | 0.666 | ||
| 1 | 20 | 56.2 (29.2–76.4) | ||||
| 2 | 3 | 66.7 (5.4–94.5) | ||||
| 3 | 1 | NA | ||||
| 6 | 1 | NA | ||||
| Conditioning regimen | chemo-MAC | 120 | 79.3 (70.7–85.6) | 0.004 | ref | |
| TBI-MAC | 129 | 58.6 (49.3–66.8) | 1.99 (1.13–3.50) | 0.017 | ||
| RIC | 50 | 82.4 (67.7–90.9) | 0.65 (0.26–1.60) | 0.350 | ||
| GVHD prophylaxis | CSA-based | 86 | 67.5 (56.2–76.4) | 0.347 | ||
| TAC-based | 208 | 71.8 (64.8–77.6) | ||||
| ATG | No | 288 | 70.6 (64.8–75.7) | 0.957 | ||
| Yes | 11 | 70.0 (32.9–89.2) | ||||
| ECOG PS | 0–1 | 262 | 71.1 (65.0–76.4) | 0.954 | ||
| 2–4 | 13 | 75.0 (40.8–91.2) | ||||
| Recipient CMV serostatus | Negative | 95 | 72.9 (62.2–81.1) | 0.877 | ref | |
| Positive | 175 | 70.3 (62.7–76.7) | 0.99 (0.61–1.62) | 0.978 | ||
| Donor recipient sex mismatch | Match | 115 | 74.3 (64.6–81.7) | 0.631 | ||
| F to M | 75 | 67.1 (55.0–76.6) | ||||
| M to F | 65 | 68.1 (54.4–78.5) | ||||
| Cytogenetic risk | Favorable | 51 | 74.0 (59.4–84.0) | 0.639 | ref | |
| Intermediate | 192 | 70.0 (62.7–76.2) | 1.34 (0.66–2.70) | 0.414 | ||
| Adverse | 56 | 69.7 (55.4–80.3) | 1.48 (0.65–3.35) | 0.349 | ||
| grade II–IV acute GVHD** | No | [-] | ref | |||
| Yes | [-] | 1.10 (0.68–1.78) | 0.705 | |||
*The median total nucleated cell and CD34 + cell doses were 6.7 × 107/kg (range, 0.01–12.3) and 1.9 × 105/kg (range, 0.01–59.4), respectively
**GVHD was treated as a time-dependent covariate in the multivariate analysis
Abbreviations: EFS, event-free survival; CI, confidence interval; HSCT, hematopoietic stem cell transplantation; TNC, total nucleated cell count; CR, complete remission; KIR, killer cell immunoglobulin-like receptor; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; TBI, total body irradiation; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; CSA, cyclosporine A; TAC, tacrolimus; ATG, antithymocyte globulin; ECOG, Eastern Cooperative Oncology Group; PS, performance status; CMV, cytomegalovirus; F, female; M, male; GVHD, graft-versus-host disease.